Table 1 Model input parameters and data sources*
Parameters | Base-case values | Data source |
|---|---|---|
Number of treatment cycles | ||
Initial treatment: pralatrexate | 2 cycles with a 7-week cycle | PROPEL study [6] |
Initial tx.: CC | 4.67 cycles with a 3-week cycle | Clinician panel survey |
Subsequent tx.: CC | 4.33 cycles with a 3-week cycle | Clinician panel survey |
Transition probability | ||
Type of distribution used to extrapolate survival curves | ||
Pralatrexate | Generalized gamma | O’Connor et al. [7] |
CC | Gompertz | O’Connor et al. [7] |
Response rate | ||
Initial treatment: pralatrexate | PROPEL study [6] | |
CR | 0.126 | |
PR | 0.211 | |
SD | 0.221 | |
PD | 0.442 | |
Initial tx.: CC | Estimation based on | |
CR | 0.198 | Korean subjects [7] |
PR | 0.214 | |
SD | 0.032 | |
PD | 0.556 | |
Subsequent tx.: CC | Estimation based on | |
CR | 0.123 | Korean subjects [7] |
PR | 0.158 | |
SD | 0.035 | |
PD | 0.684 | |
SCT rate following initial tx. | 0.529 | Clinician panel survey |
SCT success rate following initial tx. | 0.663 | Kim et al. [9] |
SCT rate following subsequent tx. | 0.458 | Clinician panel survey |
SCT success rate following subseq. tx. | 0.663 | Kim et al. [9] |
Probability of AE | ||
Mucositis (ICD-10 codes: K123) | PROPEL study [6] | |
Initial tx.: pralatrexate | 0.0172 | Crump et al. [10]; |
Initial tx.: CC | 0.0365 | Jerkeman et al. [11]; |
Subsequent tx.: CC | 0.0393 | Wang et al. [12]; |
Thrombocytopenia (D695) | Velasquez et al. [13]; | |
Initial tx.: pralatrexate | 0.0267 | Ezzat et al. [14]; |
Initial tx.: CC | 0.1122 | Press et al. [15] |
Subsequent tx.: CC | 0.0839 | |
Anemia (D611, D630) | ||
Initial tx.: pralatrexate | 0.0118 | |
Initial tx.: CC | 0.0257 | |
Subsequent tx.: CC | 0.0279 | |
Neutropenia (D70) | ||
Initial tx.: pralatrexate | 0.0172 | |
Initial tx.: conventional chemo. | 0.1250 | |
Subsequent tx.: conventional chemo. | 0.1011 | |
Nausea/vomiting (R11) | ||
Initial tx.: pralatrexate | 0.0026 | |
Initial tx.: conventional chemo. | 0.0053 | |
Subsequent tx.: conventional chemo. | 0.0070 | |
Peripheral neuropathy (G900) | ||
Initial tx.: pralatrexate | 0.0000 | |
Initial tx.: conventional chemo. | 0.0063 | |
Subsequent tx.: conventional chemo. | 0.0053 | |
Costs1 (US dollars) | ||
Medication cost2 | ||
Initial tx.: pralatrexate | $2465 | Manufacturer’s suggesting price |
Initial tx.: CC | $240 | Maximum Payable Amount Table of |
Subseq. tx.: CC | $238 | |
Concomitant drug cost | Korean NHI, Clinician panel survey | |
Initial tx.: pralatrexate | ||
First cycle, last cycle | $4, $3 | |
Initial tx.: CC | $207 | |
Subseq. tx.: CC | $198 | |
SCT cost | $27,343 | HIRA-NPS data (2011–2016), KHSCTA, KMDP |
Routine monitoring test cost | Maximum Payable Amount Table of | |
Initial tx.: pralatrexate | ||
First cycle, other cycles | $106, $17 | Korean NHI, Clinician panel survey |
Initial tx.: CC | ||
First cycle, other cycles | $129, $40 | |
Subseq. tx.: CC | ||
First cycle, other cycles | $123, $38 | |
Costs to treat AE3 | Korean NHI healthcare statistics | |
Mucositis | $1288 | |
Thrombocytopenia | $2859 | |
Anemia | $2877 | |
Neutropenia | $2760 | |
Nausea/vomiting | $707 | |
Peripheral neuropathy | $643 | |
Utility (disutility) | ||
CR | 0.885 | Kang et al. [16] |
PR | 0.784 | |
SD | 0.746 | |
PD | 0.567 | |
SCT success4: 45–49, 50–54, 55–59, 60–64 years old | 0.976, 0.971, 0.966, 0.936 | KNHANES (2014) |
Mucositis | (−0.075) | Kang et al. [16] |
Thrombocytopenia | (−0.095) | Kang et al. [16] |
Anemia | (−0.085) | Kang et al. [16] |
Neutropenia | (− 0.107) | Kang et al. [16] |
Nausea/vomiting | (− 0.059) | Nafees et al. [17] |
Peripheral neuropathy | (−0.42) | Swinburn et al. [18] |